Table 2 Statistical analysis of the results of antimicrobial susceptibility testing of 21 antibiotics for 44Â S. sonnei isolates
Antimicrobial | Antimicrobial resistance rate [No. (%)] | ||||||
|---|---|---|---|---|---|---|---|
Total (n = 44) | Gansu (n = 24) | Qinghai (n = 15) | Tibet (n = 5) | ||||
phase I (n = 20) | phase II (n = 4) | phase I (n = 10) | phase II (n = 5) | phase I (n = 3) | phase II (n = 2) | ||
Norfloxacin | 10 (22.73%) | 4 (20%) | 1 (25%) | 3 (30%) | 1 (20%) | 1 (33.33%) | 0 |
Enrofloxacin | 12 (27.27%) | 5 (25%) | 1 (25%) | 3 (30%) | 1 (20%) | 2 (66.67%) | 0 |
Levofloxacin | 4 (9.09%) | 3 (15%) | 0 | 1 (10%) | 0 | 0 | 0 |
Ciprofloxacin | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ofloxacin | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Penicillin G | 44 (100%) | 20 (100%) | 4 (100%) | 10 (100%) | 5 (100%) | 3 (100%) | 2 (100%) |
Ampicillin | 31 (70.45%) | 15 (75%) | 3 (75%) | 8 (80%) | 3 (60%) | 1 (33.33%) | 1 (50%) |
Amoxicillin/clavulanic acid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cephalothin | 13 (29.55%) | 7 (35%) | 0 | 5 (50%) | 0 | 0 | 1 (50%) |
Cephazolin | 14 (31.82%) | 7 (35%) | 1 (25%) | 5 (50%) | 0 | 0 | 1 (50%) |
Cefoxitin | 4 (9.09%) | 0 | 0 | 4 (40%) | 0 | 0 | 0 |
Ceftriaxone | 9 (20.45%) | 4 (20%) | 0 | 5 (50%) | 0 | 0 | 0 |
Cefotaxime | 5 (11.36%) | 2 (10%) | 0 | 3 (30%) | 0 | 0 | 0 |
Cefepime | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Meropenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imipenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Chloramphenicol | 4 (9.09%) | 0 | 0 | 3 (30%) | 1 (20%) | 0 | 0 |
Tetracycline | 30 (68.18%) | 14 (70%) | 2 (50%) | 8 (80%) | 3 (60%) | 2 (66.67%) | 1 (50%) |
Streptomycin | 14 (31.82%) | 5 (25%) | 2 (50%) | 5 (50%) | 1 (20%) | 0 | 1 (50%) |
Gentamicin | 12 (27.27%) | 6 (30%) | 0 | 5 (50%) | 1 (20%) | 0 | 0 |
Amikacin | 0 | 0 | 0 | 0 | 0 | 0 | 0 |